Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Peer Review reports

From: Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

Original Submission
26 Sep 2024 Submitted Original manuscript
8 Dec 2024 Reviewed Reviewer Report
2 Jan 2025 Reviewed Reviewer Report - Hiroshige Yoshioka
24 Jan 2025 Author responded Author comments - Richeng Jiang
8 Feb 2025 Reviewed Reviewer Report - Hiroshige Yoshioka
17 Feb 2025 Reviewed Reviewer Report
19 Feb 2025 Author responded Author comments - Richeng Jiang
Resubmission - Version 2
24 Jan 2025 Submitted Manuscript version 2
25 Feb 2025 Reviewed Reviewer Report - Hiroshige Yoshioka
27 Mar 2025 Author responded Author comments - Richeng Jiang
Resubmission - Version 3
27 Mar 2025 Submitted Manuscript version 3
Publishing
31 Mar 2025 Editorially accepted
15 Apr 2025 Article published 10.1186/s12916-025-04044-8

You can find further information about peer review here.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us